UiPath, Inc.
Latest List Rankings
Current Synopsis
UiPath is the software moonshot in the 5x list. The clean argument is not current growth; it is operating leverage plus a possible AI-agent re-rating if enterprise automation becomes a control layer for agentic workflows. The problem is that current ARR growth is not yet strong enough to make the 5x case obvious. PATH belongs here only as a turnaround/AI-reacceleration bet, not as a proven hypergrowth name.
Current Pillar Scores
2x model: valuation-to-growth is 93.5/100 with convexity 54.0/100; that means the score is rewarding growth-adjusted asymmetry, not cheapness in isolation. 5x model: market-cap asymmetry is 95.0/100 at roughly $6.1B current market cap, which is why size matters more here than business quality alone.
The earnings/growth score is driven by reported fundamentals, not narrative. revenue growth 17.3%, gross margin 83.0%, operating margin 7.3%, profit margin 19.6%, FCF margin 31.2%. Component support: growth acceleration 49.1, survivability 93.8.
PATH's catalyst is the possibility that automation becomes the control layer for enterprise AI agents. That is a compelling narrative, but the page needs to be honest that the current growth profile is not yet 5x-grade. The thesis depends on reacceleration and product relevance in an AI-native workflow stack.
Technical setup comes from price action, not opinion: 20-day return 9.8%, 60-day return 1.5%, 120-day return -37.2%, 60-day relative strength vs QQQ -19.9%, 1-year max drawdown -51.4%, distance from 52-week high -40.9%, 60-day annualized volatility 56.3%. Above 50dma: True; above 200dma: False.
For June this pillar is better read as options/positioning confirmation, not social-media fluff. ATM implied volatility 70.1%, call/put OI 2.3, call/put volume 3.9, OTM call OI share 62.9%, short % float 31.8%, short ratio 4.6. Component support: options asymmetry 82.1, squeeze bonus 7.0.
The base Goldilox math is roughly $6.1B current market cap versus a $12.0B bull case, or about 1.97x. That supports the 2x thesis better than the 5x thesis. The 5x case requires a true AI-agent platform re-rating and visible growth acceleration.
Current Path to Target
A 2x requires ARR acceleration, better enterprise AI adoption, and evidence that UiPath can attach itself to agentic workflows rather than be displaced by them.
The 5x case is a stretch turnaround: UiPath would need to become a core enterprise orchestration layer for AI agents, with accelerating ARR and expanding margins. The current numbers do not prove that yet, so this should be framed as conditional upside.
Current Key Risk
The risk is that UiPath remains a slower-growth automation platform while AI agents commoditize parts of the workflow stack. Without visible ARR acceleration or stronger AI-native product traction, the 5x case is more narrative than numbers.
Current Key Metrics
BRRR Appearance History
Current analysis stays canonical. This is the compact scoreboard of where the name has shown up across monthly BRRR lists.
Subscribe for monthly updates on this stock and the full rankings
Keep the latest thesis current, while the appearance history shows how conviction evolved over time.
Subscribe Free →